Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia - Nasdaq https://t.co/mAX987ikZI
— IDRO (@IDROOhio) March 1, 2019
from Twitter https://twitter.com/IDROOhio
February 28, 2019 at 10:04PM
Friday, March 1, 2019
Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia - Nasdaq https://t.co/mAX987ikZI
from Twitter https://twitter.com/IDROOhio
February 28, 2019 at 10:04PM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment